November 28, 2013 -  AbbVie announced today that Health Canada has approved Humira (adalimumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy including corticosteroids, azathioprine &/or 6-mercaptopurine (6-MP) or who are intolerant to such therapies. The efficacy of Humira in patients who have lost response to or were intolerant to TNF blockers has not been established. With this eighth indication, Humira is now approved for the treatment of the two primary diseases that comprise inflammatory bowel disease, Crohn's disease and ulcerative colitis.
For more details, go to: http://www.newswire.ca/en/story/1269903/health-canada-approves-humira-adalimumab-for-the-treatment-of-ulcerative-colitis-uc